TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22784436

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (n=200)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (n=120)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Implementation strategy
Number of subjects: 320
Study: 19403441

Group type: EXPERIMENTAL
Intervention: Individualized representational intervention to improve symptom management (IRIS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 82

Group type: COMPARATOR
Intervention: Delayed IRIS (wait list) control
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: IRIS by telephone
Number of subjects: 82
Study: 17705753

Group type: EXPERIMENTAL
Intervention: Group 1 (longer stents with proximal end in the upper calix and distal end crossing the midline of the bladder)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group 2 (proper stent length with proximal end in the pelvis and lower end just beyond the vesicoureteral junction)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 120
Study: 15377968

Group type: EXPERIMENTAL
Intervention: Practice group (serial administration of BESS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no serial administration of BESS)
Number of subjects: 50
Study: 11565240

Group type: EXPERIMENTAL
Intervention: 7-week individual self-management and coping skills training program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study: 9478251

Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal inguinal hernioplasty (TAPP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Open Lichtenstein technique
Number of subjects: 108
Study: 8176571

Group type: EXPERIMENTAL
Intervention: Early enteral feedings while LUACs were in place
Number of subjects: 29

Group type: COMPARATOR
Intervention: Late enteral feedings (24 hours after removal of LUACs)
Number of subjects: 29
Study: 2980956

Group type: COMPARATOR
Intervention: Aspirin therapy (mean duration 357 days)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Non-aspirin NSAID therapy (mean duration 67 days)
Number of subjects: 167
Study: 29397351

Group type: EXPERIMENTAL
Intervention: Coordinated multidisciplinary diabetes team care
Number of subjects: 53
Study: 28826290

Group type: EXPERIMENTAL
Intervention: One-stage surgical procedure (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Two-stage surgical procedure (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 26513240

Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simple Intervention
Number of subjects: 60
Study: 25271499

Group type: EXPERIMENTAL
Intervention: Work-focused rehabilitation
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control intervention (comprehensive or brief multidisciplinary intervention)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Work-focused rehabilitation vs Control intervention
Number of subjects: 405
Study: 22629163

Group type: EXPERIMENTAL
Intervention: Resective surgery (single-lobe/lesionectomy or multilobe resection plus multiple subpial transection and/or callosotomy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Resective surgery
Number of subjects: 18
Study: 19648982

Group type: COMPARATOR
Intervention: Usual care (high compression)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care (dressing selection)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care (pentoxifylline)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care (compression after healing)
Number of subjects: 181
Study: 17298716

Group type: EXPERIMENTAL
Intervention: Vaginal capsules of 200 mg of micronized progesterone (Utrogestan), 3 times daily
Number of subjects: 244

Group type: COMPARATOR
Intervention: Micronized progesterone in gel (Crinone 8%), once daily
Number of subjects: 244
Study: 15471654

Group type: EXPERIMENTAL
Intervention: Interest in palliative care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training in palliative care
Number of subjects: 0
Study: 11350327

Group type: EXPERIMENTAL
Intervention: Isoflurane through the agent‐saving device
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoflurane through the vaporiser
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 9542476

Group type: EXPERIMENTAL
Intervention: ABT-761 (50 to 200 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8993088

Group type: EXPERIMENTAL
Intervention: Gepirone ER (10‐60 mg/day)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Imipramine (50‐300 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Gepirone ER
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123
Study: 2400306

Group type: EXPERIMENTAL
Intervention: IOPL with saline solution
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: IOPL with saline solution and 2 g of chloramphenicol succinate
Number of subjects: 87

Group type: COMPARATOR
Intervention: No IOPL
Number of subjects: 87
Study: 6103212

Group type: EXPERIMENTAL
Intervention: Circumferential stapling gun
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional hand suturing technique
Number of subjects: 30
Study: 31742903

Group type: EXPERIMENTAL
Intervention: Walking exercise (E2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Stretching exercise (E1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 90
Study: 31385489

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy in addition to transcutaneous electrical nerve stimulation (TENS) and hot pack (HP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham magnetic field (without current flow) in addition to TENS and HP therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham magnetic field (without current flow)
Number of subjects: 0
Study: 28564564

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 910

Group type: COMPARATOR
Intervention: Control (no capecitabine)
Number of subjects: 910
Study: 25582795

Group type: EXPERIMENTAL
Intervention: Full participation group (treatment) in the extension programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actively monitored control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passively monitored control group
Number of subjects: 0
Study: 24838550

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided internal jugular cannulation (group U, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anatomic landmark guided internal jugular cannulation (group A, n=50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 22833205

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 395
Study: 21629152

Group type: EXPERIMENTAL
Intervention: Video asthma education materials
Number of subjects: 129

Group type: COMPARATOR
Intervention: Written asthma education materials
Number of subjects: 129
Study: 19054928

Group type: EXPERIMENTAL
Intervention: Sublingual-swallow immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (D.p.)/D. farinae (D.f) 50/50 extract
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 17479860

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/d)
Number of subjects: 114
Study: 12953328

Group type: EXPERIMENTAL
Intervention: Single intrauterine insemination (SIUI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Double intrauterine insemination (DIUI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (FSP)
Number of subjects: 90
Study: 10845014

Group type: EXPERIMENTAL
Intervention: Loop haptic silicone intraocular lenses
Number of subjects: 48

Group type: COMPARATOR
Intervention: Plate haptic silicone intraocular lenses
Number of subjects: 48
Study: 9732884

Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Digoxin (0.007 mg/kg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Propafenone (after crossover from placebo)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Overall treatment (Propafenone vs Digoxin)
Number of subjects: 123
Study: 7995864

Group type: EXPERIMENTAL
Intervention: SAT1
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: SAT2
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: OX3
Number of subjects: 37
Study: 3338379

Group type: EXPERIMENTAL
Intervention: Educational group meetings with NIDDM patients, consisting of three weekly lessons presented by a physician, nurse, and dietitian once every 4 months.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Educational group meetings with NIDDM patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 51
Study: 29595122

Group type: EXPERIMENTAL
Intervention: Fondaparinux (1.5 mg/d) administered subcutaneously
Number of subjects: 30
Study: 29145831

Group type: EXPERIMENTAL
Intervention: 10-week online COPD rehabilitation program (CORe) - group supervised resistance and endurance training and patient education, 60 min, three times/week at home via online screen.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional outpatient COPD rehabilitation (CCRe) - group based supervised resistance and endurance training and patient education, 90 min, two times/week for 10 weeks or 12 weeks in groups at the local hospital.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 10-week online COPD rehabilitation program (CORe)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional outpatient COPD rehabilitation (CCRe)
Number of subjects: 134
Study: 25082982

Group type: EXPERIMENTAL
Intervention: Text message intervention
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: E-mail intervention
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 246
Study: 23231379

Group type: EXPERIMENTAL
Intervention: TM81 (6 g, three times daily for 12 weeks)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo (6 g, three times daily for 12 weeks)
Number of subjects: 480
Study: 21572372

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis
Number of subjects: 47
Study: 17475527

Group type: EXPERIMENTAL
Intervention: Novolizer (12 microg formoterol twice daily)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Aerolizer (12 microg formoterol twice daily)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 392

Group type: COMPARATOR
Intervention: Aerolizer
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 392
Study: 17068305

Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 2184

Group type: COMPARATOR
Intervention: No rt-PA treatment
Number of subjects: 2184
Study: 12687029

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 microg daily propelled by HFA 134a
Number of subjects: 315

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 200 microg daily propelled by CFCs 11 and 12
Number of subjects: 315

Group type: COMPARATOR
Intervention: Comparison of FP HFA 134a vs FP CFC
Number of subjects: 315
Study: 11145492

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg daily
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg daily
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 9368159

Group type: EXPERIMENTAL
Intervention: Three-suture phacoemulsification
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: One-suture phacoemulsification
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: No-suture phacoemulsification
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sutureless phacoemulsification
Number of subjects: 131
Study: 8015532

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2895628

Group type: EXPERIMENTAL
Intervention: Corticosteroid (1 mg/kg/day) + Plasma exchange
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Corticosteroid (1 mg/kg/day) + Plasma exchange + Cyclophosphamide (2 mg/kg/day for 1 year)
Number of subjects: 72
Study: 30511149

Group type: EXPERIMENTAL
Intervention: Healthy Families Oregon (HFO) program
Number of subjects: 1438

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1438
Study: 31222572

Group type: EXPERIMENTAL
Intervention: Ajust®
Number of subjects: 205

Group type: COMPARATOR
Intervention: SMUS
Number of subjects: 205
Study: 28351523

Group type: EXPERIMENTAL
Intervention: Original delineation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Gold standard (GS) delineation
Number of subjects: 88
Study: 25456979

Group type: EXPERIMENTAL
Intervention: Prolonged continuous theta-burst stimulation (pcTBS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 14
Study: 24626980

Group type: EXPERIMENTAL
Intervention: Short-term intervention with the mother (6 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Short-term intervention with educational software program (6 weeks)
Number of subjects: 21
Study: 21355966

Group type: EXPERIMENTAL
Intervention: Volume-guaranteed pressure support (PSV-VTG)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Assisted pressure controlled ventilation (APCV)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Volume-guaranteed pressure support (PSV-VTG) and Pressure support ventilation (PSV)
Number of subjects: 28
Study: 18292433

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 16

Group type: COMPARATOR
Intervention: Verbal command
Number of subjects: 16
Study: 16537575

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 3648

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d
Number of subjects: 3648

Group type: EXPERIMENTAL
Intervention: Highest quintile of Lp-PLA2 activity
Number of subjects: 3648
Study: 14511278

Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride (up to 40 mg per day)
Number of subjects: 31
Study: 10883742

Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.63 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Racemic albuterol 2.50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.31 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9184707

Group type: EXPERIMENTAL
Intervention: Gentamicin plus ticarcillin/clavulanate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gentamicin plus ceftazidime
Number of subjects: 8

Group type: COMPARATOR
Intervention: Gentamicin plus placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gentamicin plus piperacillin
Number of subjects: 8
Study: 1383107

Group type: EXPERIMENTAL
Intervention: ABVD plus radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 2857103

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 22
Study: 29716436

Group type: EXPERIMENTAL
Intervention: Cladribine Tablets 3.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29227155

Group type: EXPERIMENTAL
Intervention: FANS (family and friends network support), a text message support curriculum synchronized to patient messages
Number of subjects: 44
Study: 26969299

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive remediation protocol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active computer control
Number of subjects: 100
Study: 25142773

Group type: EXPERIMENTAL
Intervention: CPAP pressure
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CPAP pressure cutoff of 13 cm H2O
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CPAP pressure, age, and AHI
Number of subjects: 78
Study: 22949276

Group type: EXPERIMENTAL
Intervention: Caregiver problem-solving intervention (CPSI)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 255
Study: 20205647

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study: 17646272

Group type: EXPERIMENTAL
Intervention: SOD2 Ala variant (Ex2+24T>C)
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: SOD2 Ala allele carriers with lower vitamin E intake (</=222 IU/d)
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: SOD2 Ala allele carriers with higher vitamin E intake (>222 IU/d)
Number of subjects: 3200

Group type: COMPARATOR
Intervention: SOD3 and SOD1 polymorphic variants
Number of subjects: 3200
Study: 16203930

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard stents
Number of subjects: 160
Study: 12390315

Group type: EXPERIMENTAL
Intervention: Pneumococcal and Haemophilus influenzae type b vaccines
Number of subjects: 93

Group type: COMPARATOR
Intervention: High activity antiretroviral treatment (HAART)
Number of subjects: 93
Study: 10426173

Group type: EXPERIMENTAL
Intervention: RRV-TV vaccine
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 7776542

Group type: EXPERIMENTAL
Intervention: 24 RI (reinjection at 24 hours later with 37 MBq of thallium‐201)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 24 DL (24 hours delayed imaging)
Number of subjects: 45
Study: 2184945

Group type: EXPERIMENTAL
Intervention: Aerobic exercise regimen (walking, jogging, stationary bicycling) for 30 minutes, four times a week at 65-80% maximal heart rate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Crossover to aerobic regimen after control
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control regimen (slow calisthenics and stretching) for 30 minutes, four times a week at less than 60% maximal heart rate
Number of subjects: 27
Study: 7347118

Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional monomeric contrast media
Number of subjects: 52
Study: 31706541

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich gel (APG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 48
Study: 30737333

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Interferon [IFN]‐β‐1a
Number of subjects: 589

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Patients with high baseline NfL levels
Number of subjects: 589
Study: 28623597

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 69
Study: 25482466

Group type: EXPERIMENTAL
Intervention: udenafil (50 mg) for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo (50 mg) for 12 weeks
Number of subjects: 80
Study: 23625275

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA) for atrial fibrillation (AF)
Number of subjects: 35
Study: 21483008

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) - take-home booklet with audio recording, reviewed by an oncologist
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard medical oncology consultation
Number of subjects: 207
Study: 18777127

Group type: EXPERIMENTAL
Intervention: Suture ligation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Radiowave ablation
Number of subjects: 124
Study: 16703596

Group type: EXPERIMENTAL
Intervention: GST-M1 null genotype
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Simultaneous nonnull status for both GST genotypes
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: GST-T1 null genotype and bleomycin-induced chromatid breaks
Number of subjects: 303
Study: 14996880

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of hyaluronic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-articular injection of placebo
Number of subjects: 20
Study: 11296435

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 micrograms.kg-1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 micrograms.kg-1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 45
Study: 9382907

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg twice daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Dexamphetamine (DEX) 0.15 mg/kg twice daily
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Dexamphetamine (DEX)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Continuous Performance Test
Number of subjects: 125
Study: 8195450

Group type: EXPERIMENTAL
Intervention: Imipramine (low dose: 0.5 mg/kg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (medium dose: 1.5 mg/kg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (high dose: 3.0 mg/kg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2895838

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control
Number of subjects: 217
Study: 31579909

Group type: EXPERIMENTAL
Intervention: Arm A (common protocol)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Arm B (local protocol)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Arm C (local protocol)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Arm D (local protocol)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Arm C (Trial 2)
Number of subjects: 411